Vcanbio Cell & Gene Engineering Corp., Ltd (SHA:600645)
China flag China · Delayed Price · Currency is CNY
19.41
+0.67 (3.58%)
Sep 30, 2026, 3:00 PM CST

SHA:600645 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
1,3681,4231,5501,5381,5071,497
Other Revenue
29.8232.1135.8152.0747.837.94
1,3981,4551,5851,5901,5551,535
Revenue Growth
-6.77%-8.23%-0.27%2.24%1.27%16.41%
Cost of Revenue
425.79458.73497.75505.02510.29473.84
Gross Profit
972.16996.221,0881,0851,0451,061
Selling, General & Admin
633.62650.04695.33719.77723.4749.78
Research & Development
147.49149.01182.11184.49146.12133.85
Other Operating Expenses
23.222.3419.3919.1917.5916.54
Operating Expenses
814.2843.04924.48946.57901.67937.05
Operating Income
157.96153.18163.2138.14142.93124.44
Interest Expense
-2.84-3.23-5.03-5.02-4.02-3.14
Interest & Investment Income
12.1917.924.429.5918.2316.21
Earnings From Equity Investments
-13.67-13.67-14.3-11.85-7.96-
Currency Exchange Gain (Loss)
10.214.59-3.21.51-2.370.1
Other Non Operating Income (Expenses)
-0.210.1-3.221.03-2-1.49
EBT Excluding Unusual Items
163.65158.87161.84153.4144.82136.13
Impairment of Goodwill
------19.72
Gain (Loss) on Sale of Investments
8.315.76-30.03-36.09-0.7579.09
Gain (Loss) on Sale of Assets
8.046.411.33.672.030.51
Asset Writedown
-1.36-1.35-4.68-0.31-0.8-6.26
Other Unusual Items
8.64.767.5211.929.933.2
Pretax Income
187.24174.45135.95132.59155.21222.96
Income Tax Expense
76.670.9246.5934.0348.5371.75
Earnings From Continuing Operations
110.64103.5389.3598.55106.68151.21
Minority Interest in Earnings
6.4710.3117.96.34.11
Net Income
117.11113.83100.35106.45112.99155.32
Net Income to Common
117.11113.83100.35106.45112.99155.32
Net Income Growth
60.56%13.43%-5.73%-5.78%-27.26%-
Shares Outstanding (Basic)
468455456463471471
Shares Outstanding (Diluted)
468455456463471471
Shares Change
5.93%-0.18%-1.45%-1.69%0.02%0.17%
EPS (Basic)
0.250.250.220.230.240.33
EPS (Diluted)
0.250.250.220.230.240.33
EPS Growth
51.57%13.64%-4.35%-4.17%-27.27%-

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
278.33264.07217.87210.4162.7193.22
Free Cash Flow Per Share
0.590.580.480.460.350.41
Gross Margin
69.54%68.47%68.61%68.23%67.18%69.14%
Operating Margin
11.30%10.53%10.29%8.69%9.19%8.11%
Profit Margin
8.38%7.82%6.33%6.70%7.27%10.12%
Free Cash Flow Margin
19.91%18.15%13.74%13.23%10.46%12.58%
EBITDA
233.95250.27305.17281.74253.74227.35
EBITDA Margin
16.73%17.20%19.25%17.72%16.32%14.81%
D&A For EBITDA
75.9997.09141.97143.6110.81102.91
EBIT
157.96153.18163.2138.14142.93124.44
EBIT Margin
11.30%10.53%10.29%8.69%9.19%8.11%
Effective Tax Rate
40.91%40.65%34.27%25.67%31.26%32.18%
Revenue as Reported
1,3981,4551,5851,5901,5551,535
Advertising Expenses
-26.5330.8632.9829.0232.43